Antigenics CEO Discusses Q3 2010 Results - Earnings Call Transcript

Antigenics Inc, (AGEN)

Q3 2010 Earnings Conference Call

October 28, 2010 11:00 am EST

Executives

Shalini Sharp - Antigenics - CFO

Garo Armen - Antigenics - Chairman, CEO

Analysts

Jeff Lighter - Private Investor

Eric Warrick - Private Investor

Ren Benjamin - Rodman & Renshaw

Presentation

Operator

Compare to:
Previous Statements by AGEN
» Antigenics Inc. Q2 2010 Earnings Call Transcript
» Antigenics Inc. Q1 2010 Earnings Call Transcript
» Antigenics Q3 2009 Earnings Call Transcript
» Antigenics, Inc. Q2 2009 Earnings Call Transcript

Good morning, my name is Shawn, and I’ll be your conference operator today. At this time I would like to welcome everyone to the Antigenics Third Quarter 2010 Earnings Conference Call. (Operator instructions)

Thank you. Ms. Sharp, you may begin your conference.

Shalini Sharp

Thank you, Shawn and good morning everyone. Welcome to Antigenics conference call to discuss the financial results for the quarter ended September 30^th, 2010. With me today is Dr. Garo Armen, Chairman and CEO. We hope that all of you had a chance to review the press release that was issued this morning. During this call we will review the financial results as well as provide a corporate update. We will then have a Q&A session.

Before we continue, I would like to remind you that this conference call will contain forward-looking statements including, without limitation, statements development and commercialization efforts and timelines of the company, and/or its licensees, partnering efforts, and their potential impact on the company’s programs, timing of potential royalty streams and the potential efficacy of our product candidates.

These forward looking statements are subject to risks and uncertainty that could cause actual results to differ materially. Reference to these risks and uncertainties is made in today’s press release and they are disclosed in more detail in our most recent filings with the U.S. SEC. These statements speak only as of the date of this call, and Antigenics undertakes no obligation to update or revise the statements.